We are incredibly grateful for the progress made in 2025! Here we’ve summarised this year’s significant milestones!

El Exoesqueleto ABLE ha sido incorporado en 6 hospitales públicos de Catalunya dentro de una compra centralizada del Departament de Salut, a través del Plan de Recuperación, Transformación y Resiliencia financiado por la Unión Europea-NextGenerationEU.

We are excited to announce a new official distributor: Bayber, who will commercialize our robotic exoskeleton in Portugal. This partnership marks another important milestone in our mission to democratize access to robotic rehabilitation across Europe.

We’re launching a new clinical study to evaluate the ABLE Daily, our exoskeleton designed to promote physical activity at home and in the community, and we’re looking for Dutch participants!

The ABLE Exoskeleton is now officially approved for use with Multiple Sclerosis (MS) and Neuromuscular Disorders.

Here we proudly and gratefully summarize the highlights of 2024.

The ABLE KIDS project seeks to revolutionize pediatric rehabilitation by developing the first lightweight, quick-to-adjust, frameless and accessible robotic exoskeleton for pediatric neurorehabilitation.

The Robotic-SNS project aims to transform rehabilitation in the National Health System (NHS) with the ABLE Exoskeleton, demonstrating both its efficacy and cost-effectiveness.

ABLE Human Motion has been honoured with the 2024 “Best Business Initiative” Award at the Premis Jove Empresari, organized by the Association of Young Entrepreneurs of Catalonia (AIJEC).

This year, at ABLE Human Motion, we celebrate six years of hard work, innovation, and accomplishments that have turned our mission into reality. In 2018, we embarked on a journey to develop accessible exoskeletons, and today, six years later, we are proud to see the positive impact we are achieving.

Del 17 al 19 de octubre, tuvimos el honor de participar en el Congreso de Paraplejia 2024 en Toledo, un evento clave para la investigación y tratamiento de las lesiones medulares.

At ABLE Human Motion, we are driven by the goal of redefining rehabilitation through innovative exoskeletons. As part of the Freedom Eurostars Project, which focuses on creating an exoskeleton specifically adapted for patients with Multiple Sclerosis (MS), we have been making significant strides. This project embodies our commitment to co-creation,

From September 22 to 25, ABLE Human Motion participated in the 63rd Annual Scientific Meeting of the International Spinal Cord Society (ISCoS) in Antwerp, Belgium. This prestigious event brought together experts in spinal cord injury (SCI) treatment and research, providing a platform to showcase cutting-edge solutions like the ABLE Exoskeleton.

We are thrilled to announce our New Distribution Partnership: from now on, our robotic exoskeleton will be available in Poland thanks to our new official distributor, SKYFI Sp. z o.o.!

In early April 2024, we collaborated with the Fundación Esclerosis Múltiple Madrid (FEMM) to conduct a clinical trial to validate the ABLE Exoskeleton for people affected by multiple sclerosis (MS).

We are so excited to announce our participation on the Programa d’Accés de la Innovació al Sistema de Salut de Catalunya (PASS), a BIOCAT inniative. To facilitate the access of innovation and technology to the Catalan Health System, BIOCAR in collaboration with AQuAS and CatSalut, has announced the Programa de